Article Text

Download PDFPDF

PR081/#468  Early stage ovarian immature teratoma: surveillance or chemotherapy after surgery? Experience from Chinese national center of rare disease
  1. Xinyue Zhang,
  2. Jie Yang,
  3. Ying Zhang,
  4. Jinhui Wang and
  5. Jiaxin Yang
  1. Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Obstetrics and Gynecology, Beijing, China


Introduction To compare the survival outcomes between surveillance and adjuvant chemotherapy in patients with stage I ovarian immature teratomas (IMTs) who underwent fertility-sparing surgery.

Methods In this retrospective cohort analysis, patients with stage IA Grade 2–3, stage IB and stage IC ovarian IMTs between 2011 to 2023 from PUMCH Rare Cancer Registry were identified. A shared decision about surveillance or chemotherapy was made by physician and patients or their guardians.

Results A total of 103 patients were included. As the largest tertiary referral center of gynecologic germ cell tumor in China, 75 patients (72.8%) underwent surgery in local hospitals from 21 different provinces referred to us for further treatment. Forty patients chose surveillance after surgery. The median age at diagnosis was 19 years old (range 3–37). After a mean follow-up period of 29.9 months, only one patient with stage IA grade 2 IMT who underwent cystectomy had recurrence in the same ovary. The menstruation was not affected in all patients of reproductive age. Successful pregnancy was achieved in four patients without adverse events. In chemotherapy group, 63 patients received cisplatin-based adjuvant chemotherapy. Patient age, tumor stage and grade were similar in two groups. There was no statistical difference of 3-year disease free survival (DFS) and overall survival (OS) between two groups (Log Rank p=0.325 and 0.304).

Conclusion/Implications We did not observe survival differences in recurrence between patients with stage I ovarian IMTs who underwent adjuvant chemotherapy or not. Surveillance may be safe and preferable in early stage IMT patients who underwent complete resection of tumor.

Abstract PR081/#468 Figure 1

DFS of patients of surveillance vs chemotherapy group

Abstract PR081/#468 Figure 2

OS of patients of surveillance vs chemotherapy group

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.